Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| All in, we are pleased with the first half of the fiscal year |
| As you heard from Mike, our second quarter continued the momentum we have experienced in our Healthcare segment for the past few quarters |
| But the long-term outlook for biopharma and aseptic manufacturing, which is really our sweet space is really positive, and we have a great portfolio and expect to do well |
| And, yes, one of the positive signs I saw was the significant increase in the replacement business in the last quarter or so versus the prior few periods |
| Based on these factors, our outlook continues to reflect very strong growth in the second half of the fiscal year for our AST segment as compared to the first half |
| So -- Dave, so what it does is it really gives our customers the ability to significantly improve and build much more resilient supply chains |
| Long-term, we think it's a solid mid-single digit grower |
| Overall, we are very pleased with our performance in the Healthcare segment and is anticipated to outperform our original expectations for the fiscal year, offsetting the macro challenges impacting demand in our other segments |
| procedure trends continue to shift in a positive direction, supply chain challenges have largely abated and our ability to execute and ship capital products to our delivery times has greatly improved |
| Despite these challenges, we are impressed with the ability of the business to sequentially improve margins, delivering EBIT margins above total company in the quarter |
| So we just had a great delivery quarter for capital and general cross-post businesses |
| I think the procedures have crossed over with sort of the excess inventory that was out there in the past quarter, and we're seeing very positive growth from our Medtech customers |
| I mean I think we still expect to deliver a good year in Life Sciences |
| We are increasingly confident in our expectations of a strong year for our Healthcare segment |
| We do see very positive signs of recovery in the Medtech demand |
| We saw good growth in the U.S |
| During the first half, we saw strength in replacement orders, representing 65% of our total orders in Healthcare |
| during the quarter, reflecting the improving procedure environment and the burn down of customer inventory |
| Life Sciences revenue grew 5% in the quarter on a constant currency organic basis as the delayed capital shipments from the first quarter were recognized contributing to 18% growth in capital equipment |
| We experienced double-digit growth across capital equipment, consumables and service again this quarter |
| And I would say our orders remain strong, and I mean there's so much activity out in the field in terms of our portfolio right now |
| In terms of the AST business, as I mentioned, we've seen a positive trend in the U.S |
| And that tells me that: A, our customers have confidence |
| Healthcare constant currency organic revenue grew 14% in the quarter |
| So that's just purely a timing issue, and orders remain pretty strong |
| as well as price and market share gains |
| We can -- and our field also has confidence and we can deliver in a relatively short period of time with normal lead times; and B, they're willing to spend money on a lot of pent-up maintenance CapEx that hospital systems have |
| We continue, however, to be very optimistic about the long-term trends driving demand for aseptic manufacturing in biopharma |
| For the quarter, constant currency organic revenue increased 8% driven by volume as well as 330 basis points of price |
| And we've just been able to get a lot more stuff out of our factories as we bring our lead times down pretty significantly |
| Statement |
|---|
| In addition, our performance in the quarter continued to be impacted by two short-term situations; inventory destocking in the Medtech space and the year-over-year market decline of the bioprocessing customer demand |
| Our Dental segment, second quarter revenue declined 6% on a constant currency organic basis as revenue was limited by customer destocking of inventory, in particular, for infection control products |
| EBIT margin decreased 130 basis points to 22.5% of revenue, compared with the second quarter last year, which reflects the decline in gross margin as well as the anticipated increase in year-over-year incentive compensation expense |
| We continue to see weakness, however, in the European markets where procedure recovery is taking a bit longer to take hold |
| So that negative productivity is hurting us in the short run |
| Gross margin for the quarter decreased 50 basis points compared with the prior year to 44.3% |
| Turning to AST, constant currency organic revenue declined 1% |
| In addition, from an earnings perspective, we now have an additional headwind from currency of about $0.05, which we are absorbing in our current outlook of $8.60 to $8.80 |
| Julie Winter AST volumes declined sequentially don't help margin |
| While our services business grew 5%, our capital equipment business declined due to the timing of large shipments |
| Growth will, however decelerate in the second half as we face very challenging comparisons in the fourth quarter |
| That said, there are still pockets of uncertainty, which remain outside of our Healthcare segment |
| That's been a real headwind for the first two quarters of the year |
| Just on backlog, both Healthcare and Life Sciences down sequentially |
| It did look like it was down a little bit sequentially |
| But some of these challenges facing discretionary spending, in particular, the U.S |
| There's been a lot of strikes and there's been a lot of labor shortages in Europe and just have not mobilized healthcare delivery in many places the way the U.S |
| As anticipated, our backlog has reduced as we were able to ship at a faster pace than new orders are coming in as we get back to normal lead times for our customers |
| But unfortunately, that was more than offset by lower productivity and continued material and labor inflation |
| Julie Winter Where our softness has been on the radiation side |
Please consider a small donation if you think this website provides you with relevant information